|
Cat. No.
|
CPE02
|
|
Product Overview
|
Asparaginase produced from E.Coli containing 303 amino acids and having a molecular mass of 31731 Dalton.
|
|
Description
|
Asparaginase is an enzyme that catalyzes the hydrolysis of asparagine to aspartic acid. It is marketed under the brand name Elspar, to treat acute lymphoblastic leukemia (ALL) and is also used in some mast cell tumor protocols. Unlike other chemotherapy agents, it can be given as an intramuscular, subcutaneous, or intravenous injection without fear of tissue irritation. The rationale behind asparaginase is that it takes advantage of the fact that ALL cellsare unable to synthesize the non-essential amino acidasparaginewhereas normal cells are able to make their own asparagine. These leukemic cells depend on circulating asparagine. Asparaginase however catalyzes the conversion of L-asparagine to aspartic acidand ammonia. This deprives the leukemic cell of circulating asparagine.
|
|
Formulation
|
The enzyme was lyophilized with no additives
|
|
Enzyme Commission Number
|
EC 3.5.1.1
|
|
CAS number
|
9015-68-3
|
|
Formula
|
C1377H2208N382O442S17
|
|
synonyms
|
asparaginase II; L-asparaginase; colaspase; elspar; leunase; crasnitin; α-asparaginase;L-asparagine amidohydrolase; E. coli L-asparagine amidohydrolase
|
|
Physical Appearance
|
White crystalline powder,odourless,tasteless.
|
|
Endotoxin
|
Less than 2.9u/200µ of Asparaginase
|
|
Specific activity
|
More than 250u/mg of protein calculated on the dried basis.
|
|
Purity
|
>96% by SDS-PAGE and SEC-HPLC
|
|
Stability
|
Two years when stored at -20°C, 2 weeks at 4°C.
|
|
|